Viridian Therapeutics (VRDN) is in focus after the FDA approved Lumvoa for thyroid eye disease, covering both active and chronic forms. This marks the company’s first commercial product and a new chapter for the stock.

The FDA approval has put Viridian Therapeutics back on traders’ radar, with a 30 day share price return of 23.85% and a 90 day share price return of 35.12%. However, the year to date share price return is still down 34.16%, while the 1 year total shareholder return of 17.92% points to improving sentiment over a longer window.

If Lumvoa has you looking more closely at healthcare and biotech, this could be a good moment to scan for other opportunities in similar areas through the 40 healthcare AI stocks

Viridian Therapeutics now has an approved drug, rising revenue, and a larger pipeline in motion, but the stock’s sharp recent rebound still sits against a weak year to date performance. How do those pieces compare with today’s valuation?

Preferred Price-to-Sales Multiple of 31.5x: Is it justified?

Viridian Therapeutics now trades with a P/S ratio of 31.5x, alongside a last close of $20.20 and a recent shift in sentiment after Lumvoa’s approval.

The P/S ratio compares the company’s market value to its revenue. This can be especially relevant for a business like Viridian Therapeutics that is still reporting losses but has an approved product and a developing pipeline.

Against that backdrop, Viridian Therapeutics screens as expensive on several fronts. Its 31.5x P/S ratio is above the US Biotechs industry average of 12.4x, above the peer average of 18.4x, and far above an estimated fair P/S ratio of 0.1x that our model suggests the market could shift toward if expectations reset.

Result: Price-to-Sales of 31.5x (OVERVALUED)

However, Viridian Therapeutics still reports a net loss of $303.267 million and trades at a high P/S multiple, so pipeline or commercial setbacks could quickly pressure sentiment.

Another view on Viridian Therapeutics: what the DCF model suggests

The earlier P/S check painted Viridian Therapeutics as expensive, but the SWS DCF model points in the opposite direction. At a share price of $20.20, the stock is described as trading about 87.2% below an estimated future cash flow value of $157.80, implying a very different story about upside and risk.

That kind of gap between the market price and an internally estimated fair value raises a practical question for investors: which signal deserves more weight, the rich sales multiple or the discounted cash flow view?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viridian Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around Viridian Therapeutics have you on the fence, take a closer look at the data now and form your own view with the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Viridian Therapeutics?

If Viridian Therapeutics has sharpened your focus, do not stop here. Use these targeted stock ideas to broaden your watchlist and stay aware of potential opportunities.

• Look for potential mispricing by scanning for companies that combine quality fundamentals with specific valuation characteristics through the 44 high quality undervalued stocks.
• Review companies with higher yields and particular payout profiles using the 9 dividend fortresses.
• Focus on companies with specific financial characteristics through the 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.